MedTrace Logo

Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy

NCT00691093 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 823

Last updated 2018-11-02

Study results available
· View outcomes & findings →

Summary

This is a observational study in patients treated with fesoterodine (Toviaz), who have failed on previous treatment for overactive bladder. It will collect epidemiological data and investigate the efficacy and tolerability of fesoterodine.

Conditions

Interventions

DRUG

fesoterodine

4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00691093 on ClinicalTrials.gov